REFERENCIE:

1Centers for Disease Control and Prevention.
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/assessing-risk-factors.html
2Gold, JAW, MMWR Morb Mortal Wkly Rep. 2020 Oct 23; 69 (42): 1517-1521
3Centers for Disease Control and Prevention.
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html
4Offcial Slovak MoH site korona.gov.sk
https://korona.gov.sk/wp-content/uploads/2020/04/Vcasna-terapia-rizikovych-skupin_pilot-verzia-2.0.pdf
5Interná dokumentácia MSD
6Nauck MA et al. Diabetes Obes Metab. 2007;9:194–205
7Arjona Ferreira JC et al. Diabetes Care. 2013;36:1067–1073
8Arjona Ferreira JC et al. Am J Kidney Dis. 2013;61:579–587
9Green JB et al. N Engl J Med. 2015;373:232–242
10SPC Janumet 2020 & SPC Januvia 2020
11Valensi P et al Diabetes Metab 2015;41:231-8
12Frias JP et al. Diabetes Obes Metab. 2019;21:1128–1135
13Raz, I et al Curr Med Res Opin. 2008; 24(2): 537-550
14Vilsboll et al. Diabetes Obes Metab. 2010; 12(2): 167-177
15Roussel R et al. Diabetes Obes Metab. 2019;21:781–790
16Pasquel FJ et al. Lancet Diabetes Endocrinol. 2017; 5: 125-133
17TECOS Study Group.Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating
Cardiovascular Outcomes with Sitagliptin (TECOS) Diabetes Care 2017;40:494–501 | DOI: 10.2337/dc16-1135

SKRATKY

DM 2. typu – diabetes mellitus 2. typu



Späť



SK-DIA-00071
Dátum vypracovania: február 2021